Primary Cells Market is expected to register a CAGR of 8.13% to reach USD 1,233.67 Million till 2025.
Primary human cells are isolated directly from normal human tissue or blood cells via the enzymatic or mechanical method. Primary cells retain their fundamental cellular functions. Hence, their use in cell-based research programs is increasing significantly.
Key factors that drive the primary cells market are the rapid growth in the biotechnology and biopharmaceutical industries, growing cancer research, rising adoption of primary cells over cell lines, increasing demand for monoclonal antibodies, and increasing healthcare expenditure are anticipated to drive the growth of the market during the forecast period.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5356
However, factors such as the high cost of advanced primary cells, and the risk of contamination may hamper the growth of the market. The increasing preference of primary cells in research and development to develop new drug acts as opportunities for the growth of the primary cells market.
Segment Analysis
The Global Primary Cells Market is segmented into Source, Type, and End User. By source, the market has been segmented into hematopoietic cells, skin cells, gastrointestinal cells, liver cells, lung cells, and skeletal and muscle cells.
Based on type, the market has been segmented into human primary cells and animal primary cells. On the basis of end user, the market has been segmented into pharmaceutical and biotechnology companies and research institutes.
Regional Analysis
The Global Primary Cells Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to hold the largest share of the global primary cells market. This is owing to the increasing prevalence of cancer and growing government funding in research. Also, the key players in the market are engaged in new launches and strategic collaborations to hold their market position. For instance, in January 2017, STEMCELL Technologies Inc. entered into a license agreement with Cincinnati Children’s Hospital Medical Center, to commercialize the center’s technology for producing gastrointestinal organoids from pluripotent stem cells (PSCs). Thus, all these factors are driving the primary cells market.
The European market holds the second-largest position in the global primary cells market. Factors attributing to the growth of the market include the rising prevalence of lifestyle-associated conditions, and the presence of developed economies such as Germany, the UK, and France boosts the market growth.
Asia-Pacific is estimated to be the fastest-growing region owing to the rising prevalence of chronic and acute diseases such as HIV, cancer, and diabetes, and the development of new infrastructure to support the healthcare industry are expected to drive the market growth.
The primary cells market in the Middle East & Africa is expected to grow at a significant rate owing to the implementation of a new business strategy such as a growing distribution channel, product launch in the untapped market by the healthcare companies increases the market growth in this region.
Key Players
MRFR recognizes the following companies as the Key Players in the Global Primary Cells Market—Thermo Fisher Scientific Inc. (US), AllCells (US), American Type Culture Collection (ATCC) (Virginia), Axol Bioscience Ltd (UK), Cell Biologics, Inc. (Chicago), Lonza Group, AG (Switzerland), Merck KGaA (Germany), PromoCell (UK), STEMCELL Technologies Inc. (Canada), ZenBio, Inc. (Research Triangle Park, NC), and among others.
Key Findings of the Study
- The Global Primary Cells Market was valued at USD 722.61 Million in 2018, is estimated to grow at USD 1,233.67 Million by 2025 at a CAGR of 8.13% during the assessment period
- Asia-Pacific accounted for the largest share of the global market due to the increasing per capita health spending, growing geriatric population base, and developing countries enhance the market growth
- Based on source, the hematopoietic cells segment accounted for the largest market share in 2018
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/primary-cells-market-6296
Healthcare Electronic Data Interchange Market Synopsis Market Research Future (MRFR), in its latest “Global Healthcare Electronic Data Interchange (EDI) Market” report, states that the market is expected to touch a valuation above USD 2674 Mn at 8.8% CAGR across the evaluation period.
In the healthcare sector, the enormous generate of data through documents, such as, patient records, health insurance reimbursements, and others are required to be processed and sorted for convenient extraction.
The traditional use of paper is an inefficient and cumbersome method.
The efficacy of Edi that allows the presentation of healthcare data in standardized format to institutions, healthcare professionals, and patients can prompt the expansion of the global electronic data interchange market.The rise in the adoption of EDI for performance management and operational intelligence is another determinate for the market expansion.
In addition, the growing awareness about benefits of using EDI software, adoption of EDI software by reputed pharmaceuticals, and exercising favourable funding policies offered by different healthcare companies are anticipated to spur the growth of the electronic data interchange market.On the downside, the high installation price of EDI software, hesitancy to remove conventional methods, and data security can limit the market expansion.Healthcare Electronic Data Interchange Market Key PlayersCognizant, Allscripts Healthcare Solutions Inc., Siemens Healthineers, The SSI Group, LLC, Experian Information Solutions, Inc., ZirMed Inc., GE Healthcare, McKesson Corporation, Optum, Inc., Schreiner Group, Passport Health Communications, Emdeon Inc., and HealthFusion are some reputed companies functioning in the global healthcare electronic data interchange (EDI) software market.Healthcare Electronic Data Interchange Market Segmental OutlineThe global healthcare electronic data interchange market was studied by component, transaction, delivery mode, and end user.Software and services are electronic data interchange market’s component-based segments.
The market’s transaction-based segments are payment & remittance advance, claims & encounters, claim attachments, eligibility inquiry and response, enrolments, claim status and response, and referral certification and authorization.
The cell-based assays market is projected to reach USD 18.9 billion by 2024 from USD 13.9 billion in 2019, at a CAGR of 6.3%.Consumables dominated the cell-based assays market in 2019 By product, the cell-based assays market is segmented into consumables, instruments, and services.
In 2019, the consumables segment accounted for the largest share of the market.
The large share of this product segment can be attributed to the increasing volume of R studies in pharmaceutical and biotechnology companies resulting in high demand for consumables.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=119917269 Drug Discovery held the largest share of the applications market in 2019 Based on applications, the cell-based assays market is segmented into drug discovery, basic research, and other applications such as quality checks among others.
In 2019, the drug discovery segment accounted for the largest share of the cell-based assays market.
The large share of this segment can be attributed to the increasing R investments and technological advancements in supportive processes such as high throughput screening and 3D cell cultures.North America commanded the largest share of the cell-based assay market in 2019North America commanded the largest share in the cell-based assay market.
The large share of North America in this market can be attributed to the increasing R activities by biopharma companies and increasing presence of these companies in the US is expected to increase the demand for cell-based assays product and services in this region.Request a Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=119917269Leading CompaniesThermo Fisher Scientific, Inc. (US), Danaher Corporation (Beckman Coulter, Inc.) (US), Becton, Dickinson and Company (US), GE Healthcare (US), Merck KGaA (Germany), Lonza Group (Switzerland), PerkinElmer, Inc. (US), Charles River Laboratories, Inc. (US), Cell Signaling Technologies (US), Cisbio (US), Cell Biolabs, Inc. (US), and Promega Corporation (US).
The global primary cells market size is expected to reach USD 1.79 billion by 2028 according to a new study by Polaris Market Research.The latest report on the Primary Cells market provides an in-depth analysis of the important aspects impacting the market growth, including drivers, constraints, risks, opportunities, and trends.
The research study aids in the analysis of the industry in terms of individual growth patterns, prospects, and market contributions.
Increasing investments by vendors in advancements in hydrogen storage, and increasing demand of Primary Cells vehicles further boosts the market growth.Competitive Landscape of Primary Cells MarketThe research report includes authentic information on the market shares, production capacity, growth rates, product launches and future projects of the leading firms in the Primary Cells industry.
It addresses the critical market elements that must be considered during strategic planning for both existing and new competitors in the market.
The prominent players operating in the market are:Cell Biologics, Inc., ZenBio, Inc., Stem Cell Technologies, Sigma-Aldrich, Thermo Fisher Scientific, Cureline, American Type Culture Collection, Cell Applications, Inc., Pelobiotech, Merck KGaA, Axol Bioscience Ltd, Promocell, ALLCells, Lonza Group, AG, and Creative BioarrayGet Sample Copy of Primary Cells Market Report @ https://www.polarismarketresearch.com/industry-analysis/primary-cells-market/request-for-sampleThe demand for primary cells has increased from pharmaceutical and biotechnology companies for applications such as research and development, drug discovery, testing of new drugs, cosmetics, and chemicals, and analyzing of maximum permissible dosage of new drugs.
The increasing investments in biomedical research, coupled with government initiatives support the growth of this segment.North America dominated the global primary cell culture market in 2020 and is expected to maintain its dominance over the forecast period.
